Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Vitrification Versus Slow Cooling of Human Cleavage Stage Embryos

26. november 2014 opdateret af: Bart CJM Fauser, UMC Utrecht

A Double Blinded, Randomised Controlled Trial Comparing the Effectiveness of Vitrification to Slow Cooling in Cryopreserving Human Preimplantation Embryos

Human embryos can be preserved for later transfers by freezing. Traditionally the slow cooling method has been used. About 70% of the embryos remain fully intact after thawing. However, the remaining 30% of the embryos become (partially) damaged, and this freezing damage reduces their chance to implant. Recently an ultra rapid freezing method, called vitrification has been developed. During vitrification no damaging ice crystals are formed and the embryo freezes in a glass like state.

It appears that the freezing damage is reduced when embryos are vitrified. Observational studies in humans indicate that embryos are successfully preserved by vitrification, as indicated by promising pregnancy rates following thawing. However, the effectiveness of vitrification in relation to slow cooling with respect to pregnancy rates has so far not been evaluated by a randomised, controlled trial. The aim of this study is to investigate whether vitrification significantly improves embryo survival and ongoing pregnancy rates when compared to embryos frozen by slow cooling.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

time of allocation: following embryo selection

type of embryos: cleavage stage -, morula stage or early blastocyst stage embryo (day3 - day4 after oocyte collection)

cryoprotectants: sucrose, dimethylsulfoxide, ethyleneglycol

vitrification storage device: high security vitrification straws

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

146

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Brussels, Belgien, 1090
        • Academic Hospital of Brussels
      • Utrecht, Holland, 3584 CX
        • University Medical Center of Utrecht

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 35 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • female patient age 35 years or less
  • embryos are obtained by in vitro fertilization (IVF) or intra cytoplasmatic spermatozoon injection (ICSI)
  • single embryo transfer
  • 1rst IVF/ICSI treatment with an embryo transfer
  • availability of cryopreservable embryos

Exclusion Criteria:

  • female patient age is 36 years or older
  • participants of oocyte donation program
  • participants of percutaneous spermatozoon aspiration (PESA) program
  • couples with a finite source of spermatozoa
  • absence of cryopreservable embryos

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Vitrification
The embryos of patients allocated to this arm will be cryopreserved by vitrification.
Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
Andre navne:
  • vitrification
  • high security vitrification straws
Ingen indgriben: Slow cooling
The embryos of patients allocated to this arm will be cryopreserved by the slow cooling method, which is the standard method (=no intervention)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
The percent change of the ongoing pregnancy rate per patient/couple who use their thawed embryos (following a fesh embryo transfer which did not result in an ongoing pregnancy) from baseline (slow cooling) to end point (vitrification).
Tidsramme: ongoing pregnancy is established 10 weeks following the transfer of a frozen embryo
ongoing pregnancy is established 10 weeks following the transfer of a frozen embryo

Sekundære resultatmål

Resultatmål
Tidsramme
post-thaw embryo survival rate
Tidsramme: 1 hour after thawing
1 hour after thawing
ongoing pregnancy rate per patient using their thawed embryos (independent of whether they became pregnant following a fresh embryo transfer or not
Tidsramme: 10 weeks following transfer of frozen thawed embryo
10 weeks following transfer of frozen thawed embryo
implantation rate per thawed embryo
Tidsramme: 10 weeks after transfer of thawed embryo
10 weeks after transfer of thawed embryo
implantation rate per transferred thawed embryo
Tidsramme: 10 weeks after transfer of thawed embryo
10 weeks after transfer of thawed embryo
cumulative implantation rate per cryopreservation
Tidsramme: 10 weeks after thawed embryo transfer
10 weeks after thawed embryo transfer
ongoing pregnancy rate per frozen-thaw cycle
Tidsramme: 10 weeks following thawed embryo transfer
10 weeks following thawed embryo transfer
average number of frozen-thawed cycles per patient
Tidsramme: is variable
is variable
post thaw development (categorial) per thawed embryo
Tidsramme: 24 hours following thawing
24 hours following thawing
average number of cryo-thaw cycles to ongoing pregnancy
Tidsramme: variable, up to 3 years
variable, up to 3 years
average number of thawed embryos to ongoing implantation
Tidsramme: variable, up to 3 years
variable, up to 3 years
Life birth rate
Tidsramme: 9 month after pregnancy test
9 month after pregnancy test

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Bart C Fauser, Prof.,MD,PhD, UMC Utrecht

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. maj 2009

Primær færdiggørelse (Faktiske)

1. maj 2012

Datoer for studieregistrering

Først indsendt

22. april 2009

Først indsendt, der opfyldte QC-kriterier

22. april 2009

Først opslået (Skøn)

23. april 2009

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

2. december 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. november 2014

Sidst verificeret

1. november 2014

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • Vitrification study
  • CCMO NL23499.000.08
  • METC 08/183

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner